Yinkang-002

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameYinkang-002
Drug Alias Nameanti-CD20 program (Yinkang Biopharma)
ClassificationBiologics
Mechanisms of ActionB-lymphocyte antigen CD20 inhibitors
TargetsB-lymphocyte antigen CD20
Therapy Area/IndicationsMultiple Sclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesYinkang Biopharma Inc.
China Registration ClassN/A

Develop Information

Active CompaniesYinkang Biopharma Inc.
Inactive CompaniesN/A
Active IndicationsMultiple Sclerosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A